Anixa Biosciences, Inc. (NASDAQ: ANIX) stock plunged by 3.14% in the current market trading session. Anixa is a publicly listed biotechnology firm that is working on a range of cancer and infectious disease initiatives.

ANIX stock’ Significant Update

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa’s novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, defined as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more particularly, “Follicle Stimulating Hormone Receptor-Mediated CAR-T technology.” It is being created in collaboration with Moffitt Cancer Center and has been licensed from The Wistar Institute.

It’s an autologous cell treatment that uses T-cells that have been genetically modified to address the follicle-stimulating hormone receptor (FSHR). Only the granulosa cells of the ovaries have immunologically significant amounts of FSHR. This method is also called as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a novel kind of CAR-T, because the target is a hormone receptor and the target-binding domain is generated from its natural ligand.

Moreover,

Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt, both former members of Wistar Institute, are the developers of the invention, which is titled “Methods and Compositions for Treating Cancer.” Dr. Conejo-Garcia is the Chair of Moffitt Cancer Centre’s Department of Immunology, and Dr. Perales-Puchalt is Geneos Therapeutics’ Vice President of Research and Development. The patent has been issued to The Wistar Institute, and Certainty Therapeutics, Inc., a majority-owned subsidiary of Anixa Biosciences, is the sole worldwide licensee. This patent belongs to the same family as the first one, and it includes further intellectual property linked to Anixa’s CAR-T technology.

Dr. Amit Kumar, President, and CEO of Anixa Biosciences commented,

They are glad to receive this letter from the USPTO, which confirms that their unique CAR-T cancer therapy technique has been granted further protection. This technique targets malignancies by utilizing particular hormone-to-hormone receptor biology, and it has the potential to be the first effective CAR-T treatment for solid tumors. While their first emphasis is on the cure of ovarian cancer, with clinical trials set to start before the end of the year, the method described by the patent is wide and may be used to treat various solid tumors by utilizing an anti-angiogenesis mode of action.